Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Daniel Ambrosio, Michael Benatar et al.|The Lancet Neurology|2017

Cited by 820